title: Improvement of anger at one week predicts the effects of sertraline and placebo in PTSD.
abstract: In previous work we demonstrated an early, robust and sustained effect for sertraline vs placebo on irritability and anger in subjects with PTSD. In this report, we explore the same dataset to assess whether a clinician might usefully predict ultimate response to sertraline, on the basis of its effect upon anger after one week. Three hundred and eighteen subjects were assessed. Outcome was measured by whether or not the score was reduced by at least 50% from baseline. Ordinary least squares regression was used to estimate the effects of change in anger at one week. Logistic regression was applied to estimate the effects on odds of a 50% drop in score. Cut points were developed for one-week change scores on anger for sertraline and placebo. The best cut point was selected as predictive of non-response, i.e. a cue suggesting that treatment switch would be in order. An increase in anger of 30% at one-week best predicted the likelihood of not responding to treatment in both the drug and placebo groups. Twenty-five percent of all non-responders were incorrectly identified, while only 7% of all improvers were incorrectly categorized as non-responders using this cutoff. Our findings imply that, for patients similar to those in this study, an increase in anger after one week of treatment might be one factor to consider when making a decision about continuation of the medication.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Trent Drive, Yellow Zone, Box 3812, 4th Floor, Room 4082B, Durham, NC 27710, USA. jonathan.davidson@duke.edu
authors.forename: Jonathan
authors.initials: J
authors.lastname: Davidson
authors.forename: Lawrence R
authors.initials: LR
authors.lastname: Landerman
authors.forename: Cathryn M
authors.initials: CM
authors.lastname: Clary
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000786:Anger; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011379:Prognosis; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D020280:Sertraline / Q000494:pharmacology*; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy* / Q000523:psychology*; D016896:Treatment Outcome
chemical_list: D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline